Timothy Collier (Presenter)
Cleveland HeartLab Inc
Bio: Ph.D. - 2010, NC State University under David Muddiman in Quantitative Proteomics Post-Doc - 2010-2013, Washington University in St. Louis under Ron Bose using quantitative mass proteomics to characterize signal dynamics of drug resistant breast cancers. Currently Research and Development Scientist at Cleveland Heartlab under Cory Bystrom developing new quantitative proteomic assays of diagnostic or prognostic value in Cardiovascular Health.
| Short Abstract The final segment of this session will discuss the use of mass spectrometry-based proteomics for clinical applications with examples from the literature and real-world applications. Specific attention will be given to technological and performance advantages of those methods and how otherwise unmet clinical needs are addressed. This segment will conclude with an overview of new techniques, technologies, and development strategies that present opportunities for further advancement in the field. |
Long Abstract
The final segment of this session will discuss the use of mass spectrometry-based proteomics for clinical applications with examples from the literature and real-world applications. Specific attention will be given to technological and performance advantages of those methods and how otherwise unmet clinical needs are addressed. This segment will conclude with an overview of new techniques, technologies, and development strategies that present opportunities for further advancement in the field.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | yes | Cleveland HeartLab, Inc. |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |